Strategien zur Reduzierung der Kupferaufwandmengen im ökologischen Kartoffelanbau – Projekt “ÖKO-SIMPHYT“

Potato late blight (Phytophthora infestans) is still an unsolved problem in organic farming. Up to now the disease can only be controlled by copper fungicides. Our project is aiming to reduce the application of copper-containing fungicides by introduc-tion of the new blight forecasting system “ÖKO-SIMPHYT” based on meteorological parameters. Primary stem infections should be reduced by seed treatment with copper fungicides thus to postpone the beginning of the blight epidemic as well as the start of spraying. To control secondary infections on the foliage, fungicide strategies should be elaborated to achieve best efficacy with reduced amounts of copper. Therefore copper amounts and spraying intervals should be adjusted to the infection pressure. Based on the biological and epidemiological conditions for primary and secondary infections the new developed potato blight forecast system ÖKO-SIMPHYT should be optimized

Kupferminimierungsstrategien im ökologischen Kartoffelanbau – Projekt “ÖKO-SIMPHYT“: Erste Erfahrungen aus dem norddeutschen Freiland

In the research project „ÖKO-SIMPHYT“ different strategies are tested to reduce the copper application for Phytophthora infestans in organic potato cultivation. Within the first two years of our research a reduction of the total amount of copper per hectare could be accomplished when applying the new developed forecast system ÖKO-SIMPHYT. With this decision support system a reduction of copper up to 46% was possible, when the infection pressure was relatively low. These first results have now to be proven under high infection pressure conditions. Experiments were carried out in the greenhouse to test the rain stability of copper and contacting agents. It could be proved that precipitation of 30 mm is able to reduce the degree of a copper treatment by up to 25%

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial

Background Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer. However, it is not known whether anastrozole is more effective than tamoxifen for women with hormone-receptor-positive ductal carcinoma in situ (DCIS). Here, we compare the efficacy of anastrozole with that of tamoxifen in postmenopausal women with hormone-receptor-positive DCIS. Methods In a double-blind, multicentre, randomised placebo-controlled trial, we recruited women who had been diagnosed with locally excised, hormone-receptor-positive DCIS. Eligible women were randomly assigned in a 1:1 ratio by central computer allocation to receive 1 mg oral anastrozole or 20 mg oral tamoxifen every day for 5 years. Randomisation was stratified by major centre or hub and was done in blocks (six, eight, or ten). All trial personnel, participants, and clinicians were masked to treatment allocation and only the trial statistician had access to treatment allocation. The primary endpoint was all recurrence, including recurrent DCIS and new contralateral tumours. All analyses were done on a modified intention-to-treat basis (in all women who were randomised and did not revoke consent for their data to be included) and proportional hazard models were used to compute hazard ratios and corresponding confidence intervals. This trial is registered at the ISRCTN registry, number ISRCTN37546358. Results Between March 3, 2003, and Feb 8, 2012, we enrolled 2980 postmenopausal women from 236 centres in 14 countries and randomly assigned them to receive anastrozole (1449 analysed) or tamoxifen (1489 analysed). Median follow-up was 7·2 years (IQR 5·6–8·9), and 144 breast cancer recurrences were recorded. We noted no statistically significant difference in overall recurrence (67 recurrences for anastrozole vs 77 for tamoxifen; HR 0·89 [95% CI 0·64–1·23]). The non-inferiority of anastrozole was established (upper 95% CI <1·25), but its superiority to tamoxifen was not (p=0·49). A total of 69 deaths were recorded (33 for anastrozole vs 36 for tamoxifen; HR 0·93 [95% CI 0·58–1·50], p=0·78), and no specific cause was more common in one group than the other. The number of women reporting any adverse event was similar between anastrozole (1323 women, 91%) and tamoxifen (1379 women, 93%); the side-effect profiles of the two drugs differed, with more fractures, musculoskeletal events, hypercholesterolaemia, and strokes with anastrozole and more muscle spasm, gynaecological cancers and symptoms, vasomotor symptoms, and deep vein thromboses with tamoxifen. Conclusions No clear efficacy differences were seen between the two treatments. Anastrozole offers another treatment option for postmenopausal women with hormone-receptor-positive DCIS, which may be be more appropriate for some women with contraindications for tamoxifen. Longer follow-up will be necessary to fully evaluate treatment differences

Controlling the net: European approaches to content and access regulation

This article has been accepted for publication in the journal, Journal of Information Science [© CILIP] and the final (edited, revised and typeset) version of this paper will be published in Journal of Information Science, by SAGE Publications Ltd, All rights reserved. © CILIP. For more information please visit: http://jis.sagepub.co.uk

Value assessment of e-maintenance platforms

No description supplie